On October 15, 2026, the shareholders of Supernus Pharmaceuticals, Inc. (SUPN) approved the proposed merger with and into a subsidiary of Indivior Pharmaceuticals, Inc. (INDV). As a result of the merger, Supernus Pharmaceuticals, Inc. (SUPN) will be suspended from Nasdaq and Indivior Pharmaceuticals, Inc. will have a name and symbol change to Supernus, Inc., using the symbol SUPN previously used by Supernus Pharmaceuticals, Inc., effective November 3, 2026.

Nasdaq requests that market data redistributors note this is a symbol reuse and history should NOT carry over from the current SUPN to the new SUPN effective Tuesday, November 3, 2026. The history from INDV should carry over to SUPN effective November 3, 2026.